Compare YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF vs Recursion Pharmaceuticals Inc — how do they compare? YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $40, while Recursion Pharmaceuticals Inc trades at $3.03 (market cap $1.63B). The key difference: YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| QDTY | RXRX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $46.71 | $6.79 |
52-Week Low | $36.57 | $2.84 |
Market Cap | — | $1.63B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTY trades at $39.53 with minimal daily movement (+0.15%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, while oscillators remain neutral. The stock faces immediate resistance at $40 and support at $39. Recent corporate actions include consistent weekly dividend distributions, with amounts ranging from $0.22 to $0.32 per share throughout 2026.
The outlook remains cautious given the bearish technical signals and lack of available fundamental data. While the consistent dividend payments provide some income stability, the absence of key financial metrics like P/E ratio and profitability measures limits fundamental analysis. Investors face uncertainty regarding the company's financial health and growth prospects without current earnings data.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
